从脂肪酸代谢水平阐释“异病同证”、“同证同理”等维医基础理论的科学性以及探讨不同肿瘤异常黑胆质证患者体内脂肪酸代谢变化。肿瘤病异常黑胆质证患者122 例，其中包括食管癌患者25例、肠癌患者20 例、肺癌患者33 例、乳腺癌患者20 例和胃癌患者24 例；另选35例健康志愿者为对照组；采用气相色谱法（gas chromatography，GC）对患者血浆进行10 种脂肪酸的定量检测；对患者与健康对照组之间的不同脂肪酸含量的差异性采用SPSS 16.0 软件进行独立样本的t 检验。结果显示，肉豆蔻酸在食管癌、肠癌、肺癌、乳腺癌和胃癌异常黑胆质证患者体内的含量均明显升高，这是本研究中所有肿瘤患者共同的特点；食管癌异常黒胆质证患者体内棕油酸、油酸、花生酸和DHA 含量明显升高，而亚油酸、花生四烯酸含量明显降低；肠癌异常黑胆质证患者体内棕榈酸和油酸含量明显升高；肺癌异常黑胆质证患者体内棕油酸、棕榈酸、油酸和花生酸含量明显升高，而亚油酸含量明显降低；乳腺癌异常黑胆质证患者体内棕油酸、棕榈酸、油酸、花生酸和EPA 含量明显升高，而硬脂酸和花生四烯酸含量明显降低；胃癌异常黑胆质证患者体内的棕油酸和DHA 含量明显升高，而亚油酸、EPA 和花生四烯酸含量明显降低。由此得出，不同病种肿瘤异常黑胆质证患者血浆脂肪酸代谢特点有共性，也有明显的差异性。
To investigate the plasma fatty acid metabolism of different cancer patients with abnormal Savda in Uyghur medicine and analyze its common features, the plasma fatty acid concentration was tested by the gas chromatography (GC) from 122 cases of cancer patients with abnormal Savda including 25 cases of esophageal cancer, 20 cases of colorectal cancer, 33 cases of lung cancer, 20 cases of breast cancer and 24 cases of gastric cancer, and 35 healthy volunteers as a control group. The spectral profiles were subjected to a t-test for statistical significance. The results show that compared to the healthy group, the patients of esophageal cancer, colorectal cancer, lung cancer, breast cancer and gastric cancer with abnormal Savda suffer a high concentration of myristic acid; the patients of esophageal cancer, lung cancer, breast cancer and gastric cancer with abnormal Savda suffer a high concentration of palm acid; the patients of colorectal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of palmitic acid; the patients of esophageal cancer, lung cancer and gastric cancer with abnormal Savda suffer a low concentration of linoleic acid; the patients of esophageal cancer, colorectal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of oleic acid; the patients of breast cancer patients with abnormal Savda suffer a low concentration of stearic acid; the patients of esophageal cancer and gastric cancer with abnormal Savda suffer a low concentration of arachidonic acid; the patients of breast cancer patients with abnormal Savda suffer a high concentration of EPA, but the patients of gastric cancer with abnormal Savda suffer a low concentration of EPA; the patients of esophageal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of arachidic acid; the patients of esophageal cancer and gastric cancer with abnormal Savda suffer a high concentration of DHA. It is concluded that these findings suggest that different tumor patients with abnormal Savda see some common characteristics, and also significant differences.
[1] 易沙克江. 中国医学百科全书. 维吾尔医分卷(维吾尔文)[M]. 乌鲁木 齐: 新疆科技卫生出版社, 1985. Ishakjan. The encyclopedia of Uyghur traditional medicine[M]. Urumqi: Xinjiang Science and Technology Publishing House, 1985.
[2] 买买提明·沙比尔. 维吾尔医学诊断学[M]. 乌鲁木齐: 新疆科技卫生 出版社, 1993. Sabir Mamatimin. Diagnostics of Uyghur medicine[M]. Urumqi: Science and Technology Publishing Company in Xinjiang, 1993.
[3] 哈木拉提·吾甫尔. 维吾尔医学体液论及其现代研究[M]. 乌鲁木齐: 新疆科技卫生出版社, 2003. Halmurat Upur. Therapy of Mizaj and Hilit in Uyghur medicine and modern study[M]. Urumqi: Science and Technique Publishing Company in Xinjiang, 2003.
[4] 库热西江·托乎提, 阿不都热依木·玉素甫, 哈木拉提·吾甫尔, 等. 维 吾尔医正常体液与异常体液分型比较研究[J]. 中国民族医药杂志, 2004(3): 3-4 Tohti Kurash, Yusup Abdurehim, Upur Halmurat, et al. Classify study on normal and unnormal physique fluid of Uyghur raditional medicine[J]. Journal of Medicine & Pharmacy of Chinese Minorities, 2004(3): 3-4.
[5] 哈木拉提·吾甫尔, 阿不都热依木·玉苏甫, 吐尔逊·吾甫尔, 等. 维医 异常体液分型与年龄、性别关系的探讨[J]. 中国民族民间医药杂志, 2003(2): 84-86. Upur Halmurat, Yusup Abdurehim, Upur Tursun, et al. An approach to the relation of types of abnormal body-liquid and sexuality or age in Uyghur nationality medicine[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2003(2): 84-86.
[6] 哈木拉提·吾甫尔, 阿不都热依木·玉苏甫. 维吾尔医异常黑胆质新论[M]. 乌鲁木齐: 新疆人民出版社, 2009. Upur Halmurat, Yusup Abdurehim. The new theory of abnormal savda Hilit in Uyghur medicine[M]. Urumqi: Xinjiang People's Publishing House, 2009.
[7] Torelli G F, Cascino A, Muscaritoli M, et al. Energy metabolism in cancer patients[J]. Minerva Gastroenterologicae Dietologica, 1997, 43(4): 183-188.
[8] Bradbury K E, Skeaff C M, Green T J, et al. The serum fatty acids myristic acid and linoleic acid are better predictors of serum cholesterol concentrations when measured as molecular percentages rather than as absolute concentrations[J]. The American Journal of Clinical Nutrition, 2010, 91(2): 398-405.
[9] Zöllner A, Dragan C A, Pistorius D, et al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid[J]. Biological Chemistry, 2009, 390(4): 313-317.
[10] Mamtimin B, Upur B, Hao F, et al. Plasma metabonomic analysis with 1H nuclear magnetic resonance revealing the relationship of different tumors and the disease homology theory of traditional Uyghur medicine[J]. Chinese Journal of Integrative Medicine, 2011, 17(2): 111-115.
[11] 艾斯克尔·吐拉洪, 哈木拉提·吾甫尔, 豪富华, 等. 基于NMR的维吾 尔医异常黑胆质型肿瘤患者血浆代谢组学分析[J]. 科技导报, 2009, 27(13): 27-31. Turahun Askar, Upur Halmurat, Hao Fuhua, et al. Metabonomic studies on abnormal savda syndrome patients with neoplasm using nmr spectroscopy[J]. Science & Technology Review, 2009, 27(13): 27-31.
[12] 巴吐尔·买买提明, 哈木拉提·吾甫尔, 豪富华. 异常黑胆质型与非异 常黑胆质型肿瘤患者血浆代谢组学差异分析[J]. 科技导报, 2009, 27 (20): 39-43. Mamtimin Batur, Upur Halmurat, Hao Fuhua. Metabonomic differences of plasma between abnormal Savda and Unsavda syndrome neoplasm patients[J]. Science & Technology Review, 2009, 27(20): 39-43.
[13] Calder P C. Polyunsaturated fatty acids, inflammation, and immunity[J]. Lipids, 2001, 36(9): 1007-1024.
[14] 陈龙, 王丙云, 毛鑫智. 动物肝损伤组织花生四烯酸代谢物水平的变 化[J].南京师范大学学报: 自然科学版, 2000, 24(1): 62-66. Chen Long, Wang Bingyun, Mao Xinzhi. Changes of arachidonic acid metabolites of liver injury tissue in animals[J]. Journal of Nanjing Normal University: Natural Science Edition, 2000, 24(1): 62-66.
[15] 刘冀红, 曹新伟. n-3多不饱和脂肪酸在肿瘤防治中的意义[J]. 肠外 与肠内营养, 2004, 11(1): 55-57. Liu Jihong, Cao Xinwei. Effects of n-3 fatty acids on prevention and therapy of tumor[J]. Parenteral & Enteral Nutrition, 2004, 11(1): 55-57.
